AOD-9604: what the studies show

The negative obesity trial

AOD-9604 is a modified fragment of human growth hormone. Its proposed fat-metabolism effects did not translate into convincing weight loss in the large OPTIONS trial. FDA reports that 536 adults enrolled and 502 were randomized. Oral treatment did not outperform placebo on weight loss at the 12-week primary endpoint.

The study continued for 24 weeks with diet and exercise support. The sponsor ended development for obesity in 2007. Earlier mechanistic claims do not reverse that negative clinical result.

Match the route to the evidence

The large study used tablets taken daily under a research protocol. That trial does not establish a self-use regimen. The published human report describes oral and intravenous studies. It cannot establish effectiveness or long-term safety for subcutaneous preparations marketed for fat loss.

What remains unproven

FDA has approved no AOD-9604 drug. Its assessment found insufficient evidence for obesity treatment by any route. The original human publication largely reports safety. Favorable tolerability findings do not establish weight-loss efficacy. A convincing clinical benefit would need direct evidence for a defined formulation and population.